Demodex blepharitis is a pervasive and damaging ocular disease that occurs across the United States1-3
  • Prevalence
  • Patient Burden
  • Identification

Demodex Blepharitis

Demodex mites are associated with over 2/3 of blepharitis cases in the US, which are characterized by eyelid inflammation, redness, and irritation.2,4

According to published literature, of the 45 million people who visit eye care clinics annually, 58% have collarettes, a pathognomonic sign of Demodex blepharitis.

There are

~25 million

people with Demodex blepharitis1,5,6

shape

Collarettes can be frequently found in common patient groups1,7

Titan study: a large-scale retrospective chart review of an all-comer population across 7 US sites examining the presence of collarettes and other characteristics
(N=1037)

stat-people
stat-people
stat-people
stat-people
stat-people
1.5 Million

Blepharitis
w/Demodex
Diagnosed

1.2 Million

Dry Eye Rx Patients
With Demodex

2.2 Million

Cataract Patients
With Demodex

2.3 Million

Contact Lens Intolerant Patients
With Demodex

~18 Million

Demodex Patients Visiting
Eye Doctors

stat-people
1.5 Million

Blepharitis
w/Demodex
Diagnosed

stat-people
1.2 Million

Dry Eye Rx Patients
With Demodex

stat-people
2.2 Million

Cataract Patients
With Demodex

stat-people
2.3 Million

Contact Lens Intolerant Patients
With Demodex

stat-people
~18 Million

Demodex Patients Visiting
Eye Doctors

80%
of patients say Demodex blepharitis has a negative impact on their daily lives.3
In the Atlas study, the majority of patients experienced2:
  • Signs and symptoms for >4 years
  • Top symptoms of itchy eyes or dryness either frequently or all the time
  • 58% of patients were never diagnosed with Demodex blepharitis
When asked how Demodex blepharitis affects their daily lives, most patients reported3:
  • Difficulty wearing makeup
  • Constantly worrying about their eyes
  • Difficulty driving at night
  • Negative appearance of eyes or eyelids

Learn how Demodex mites cause blepharitis

Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasite found on humans. There are two species of Demodex—D folliculorum and D brevis—that live on the skin of the face and eyelids.

Demodex folliculorum

Demodex
folliculorum

Demodex brevis

Demodex brevis

Demodex blepharitis can be hiding in plain sight

Demodex blepharitis can be confidently diagnosed by looking for collarettes during a routine slit lamp exam. When present, collarettes are easily seen along the lash line of the upper lid margin when your patient looks down.

Slit lamp evaluation, 1.0x magnification Patient looking straight ahead in a slit lamp.
Patient looking straight ahead
Patient looking straight ahead with lid lift
Slit lamp evaluation, 1.0x magnification Patient looking down in a slit lamp.
Patient looking down, diffuse collarettes

Published literature has shown that 100% of patients with collarettes have Demodex blepharitis.6

References

1. Sadri E, Yeu E, Trattler W, Holdbrook M, Baba S. The prevalence of collarettes and Demodex blepharitis in ophthalmology and optometry practices. Presented at: ASCRS 2021. Abstract 75009. 2. Schachter S, Yeu E, Holdbrook M, Baba S, Gomes PJ. Clinical manifestations of Demodex blepharitis. Presented at: ARVO 2021. Abstract 3546575. 3. Yeu E, Holdbrook M, Baba S, Gomes PJ. Psychosocial impact of Demodex blepharitis. Presented at: ARVO 2021. Abstract 3544849. 4. Boyd K. What is blepharitis? American Academy of Ophthalmology. Published June 30, 2021. Accessed July 8, 2021. https://www.aao.org/eye-health/diseases/what-is-blepharitis 5. Wilson FA, Stimpson JP, Wang Y. Inconsistencies exist in the national estimates of eye care services utilization in the United States. J Ophthalmol. doi:10.1155/2015/435606 6. Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094. 7. Data on file. Tarsus Pharmaceuticals, Inc. May 2021.

Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.